A single center, open-label trial of isavuconazole prophylaxis against invasive fungal infection in patients undergoing allogeneic hematopoietic cell transplant (HCT)

Hematopoietic cell transplantation (HCT) is associated with a high risk of invasive fungal infections (IFI). Fluconazole is approved in the United States for Candida prophylaxis during HCT, but it does not provide coverage against molds [1]. Voriconazole, a broad-spectrum triazole active against Candida and Aspergillus species, has been increasingly used for antifungal prophylaxis for high risk HCT such as cord blood HCT and ex vivo T-cell depleted HCT recipients [2 –4]. In a randomized trial of voriconazole versus fluconazole prophylaxis in standard risk HCT recipients, the overall rates of IFI and fungal free survival at 6 and 12 months were similar in the two arms.

Source: Biology of Blood and Marrow Transplantation - February 19, 2020 Category: Hematology Authors: Anat Stern, Yiqi Su, Yeon Joo Lee, Susan Seo, Brian Shaffer, Roni Tamari, Boglarka Gyurkocza, Juliet Barker, Yael Bogler, Sergio Giralt, Miguel Perales, Genovefa A. Papanicolaou Source Type: research